HUP0301877A2 - Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek - Google Patents

Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek

Info

Publication number
HUP0301877A2
HUP0301877A2 HU0301877A HUP0301877A HUP0301877A2 HU P0301877 A2 HUP0301877 A2 HU P0301877A2 HU 0301877 A HU0301877 A HU 0301877A HU P0301877 A HUP0301877 A HU P0301877A HU P0301877 A2 HUP0301877 A2 HU P0301877A2
Authority
HU
Hungary
Prior art keywords
antitumors
agents
monoclonal anti
aromatase inhibitors
her2 antibodies
Prior art date
Application number
HU0301877A
Other languages
English (en)
Inventor
Giorgio Massimini
Gabriella Piscitelli
Dinesh Purandare
Original Assignee
Pharmacia & Upjohn Co.
Pharmacia Italia S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co., Pharmacia Italia S.P.A filed Critical Pharmacia & Upjohn Co.
Publication of HUP0301877A2 publication Critical patent/HUP0301877A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány a HER2 túlzott kifejezésével jellemezhető hormonfüggőbetegségek kezelésével foglalkozik. Részletesebben, a találmány a HER2túlzott kifejezésével jellemezhető hormonfüggő betegséggeldiagnosztizált vagy jellemzett, erre érzékeny humán betegek anti-HER2ellenanyag és aromáz inhibitor kombinációval történő kezelésérevonatkozik. Ó
HU0301877A 2000-05-15 2001-04-19 Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek HUP0301877A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (1)

Publication Number Publication Date
HUP0301877A2 true HUP0301877A2 (hu) 2003-09-29

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301877A HUP0301877A2 (hu) 2000-05-15 2001-04-19 Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek

Country Status (20)

Country Link
EP (1) EP1282440A1 (hu)
JP (1) JP2003533490A (hu)
KR (1) KR20030014223A (hu)
CN (1) CN1429118A (hu)
AU (1) AU784617B2 (hu)
BR (1) BR0110732A (hu)
CA (1) CA2409652A1 (hu)
CZ (1) CZ20023748A3 (hu)
EA (1) EA005931B1 (hu)
EE (1) EE200200622A (hu)
HK (1) HK1054200A1 (hu)
HU (1) HUP0301877A2 (hu)
IL (1) IL152389A0 (hu)
MX (1) MXPA02011194A (hu)
NO (1) NO20025302L (hu)
NZ (1) NZ523004A (hu)
PL (1) PL360153A1 (hu)
SK (1) SK16022002A3 (hu)
WO (1) WO2001087334A1 (hu)
ZA (1) ZA200209815B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
ES2331646T3 (es) 2000-05-19 2010-01-12 Genentech, Inc. Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
DK1377298T3 (da) * 2001-01-26 2007-01-02 Pfizer Italia Srl Exemestan til behandling af hormon-afhængige lidelser
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
NZ552091A (en) * 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
MX2012008958A (es) 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013081645A2 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN104220457A (zh) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 涉及her3抑制剂的诊断和治疗
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
SG11201703279XA (en) 2014-10-22 2017-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2018534291A (ja) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
US11524014B2 (en) 2019-06-03 2022-12-13 Havah Therapeutics Pty Ltd. Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
CZ20023748A3 (cs) 2003-04-16
WO2001087334A1 (en) 2001-11-22
HK1054200A1 (zh) 2003-11-21
IL152389A0 (en) 2003-05-29
PL360153A1 (en) 2004-09-06
CN1429118A (zh) 2003-07-09
MXPA02011194A (es) 2003-03-10
JP2003533490A (ja) 2003-11-11
NO20025302D0 (no) 2002-11-05
EE200200622A (et) 2004-06-15
EP1282440A1 (en) 2003-02-12
CA2409652A1 (en) 2001-11-22
KR20030014223A (ko) 2003-02-15
EA005931B1 (ru) 2005-08-25
AU784617B2 (en) 2006-05-18
NO20025302L (no) 2002-11-05
SK16022002A3 (sk) 2003-04-01
AU5630901A (en) 2001-11-26
BR0110732A (pt) 2003-02-04
ZA200209815B (en) 2003-12-03
NZ523004A (en) 2004-09-24
EA200201213A1 (ru) 2003-04-24

Similar Documents

Publication Publication Date Title
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
NO20056236L (no) Behandling med anti-VEGF-antistoffer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
ATE364618T1 (de) Antikörper gegen das muc18-antigen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NI200700021A (es) Anticuerpos dirigidos contra péptido beta-amiloide y procedimientos que usan los mismos. pc19496a
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
AT500379B1 (de) Tau-proteine
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
HUP0301835A2 (hu) Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EA200702064A1 (ru) Новое анти-plgf антитело
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
MXPA05010914A (es) Metodo de tratamiento de la enfermedad de alzheimer.
DE60112744T2 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
ATE473760T1 (de) Monoklonale antikörper gegen den hepatozyten- wachstumsfaktor

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees